NCT05951049View on ClinicalTrials.gov

A Study of AT-02 in Subjects With Systemic Amyloidosis.

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

September 21, 2023

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Amyloidosis; Systemic
Interventions
DRUG

AT02

Dosage Form: Solution for injection/infusion Dosage level: Different dose levels of AT02 Route of Administration: Intravenous use

Trial Locations (4)

19104

RECRUITING

Penn Presbyterian Medical Center, Philadelphia

44195

RECRUITING

Cleveland Clinic, Cleveland

64111

RECRUITING

Kansas City, Kansas City

97239

NOT_YET_RECRUITING

OHSU (Oregon Health & Science University), Portland

Sponsors

Lead Sponsor

Attralus, Inc.
All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

Attralus, Inc.

INDUSTRY

NCT05951049 - A Study of AT-02 in Subjects With Systemic Amyloidosis. | Biotech Hunter | Biotech Hunter